Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 3Thoracic 2Gastrointestinal 2Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Colorectal Neoplasms 751Pancreatic Neoplasms 665Stomach Neoplasms 387Carcinoma, Non-Small-Cell Lung 375Carcinoma, Hepatocellular 368Breast Neoplasms 316Colonic Neoplasms 279Ovarian Neoplasms 260Neoplasms 250Esophageal Neoplasms 237Neoplasm Metastasis 215Rectal Neoplasms 202Melanoma 195Lung Neoplasms 193Liver Neoplasms 180Squamous Cell Carcinoma of Head and Neck 150Carcinoma, Renal Cell 146Head and Neck Neoplasms 124Prostatic Neoplasms 123Triple Negative Breast Neoplasms 109Uterine Cervical Neoplasms 106Urinary Bladder Neoplasms 106Cholangiocarcinoma 104Endometrial Neoplasms 101Sarcoma 99Small Cell Lung Carcinoma 74Gastrointestinal Neoplasms 73Esophageal Squamous Cell Carcinoma 68Kidney Neoplasms 63Carcinoma, Transitional Cell 60

Interventions

trametinib 1spartalizumab 1pembrolizumab 1nazartinib 1canakinumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Ductal × Gastrointestinal × Clear all
NCT04660929 2024-12-18

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Carisma Therapeutics Inc

Phase 1 Unknown
48 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Ovarian Epithelial, Adenocarcinoma, Bile Duct Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Small Cell, Carcinoma, Ductal, Small Cell Lung Carcinoma, Inflammatory Breast Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔